Celecoxib pathways: pharmacokinetics and pharmacodynamics.
作者信息
Gong Li, Thorn Caroline F, Bertagnolli Monica M, Grosser Tilo, Altman Russ B, Klein Teri E
机构信息
Department of Genetics, Stanford University, Stanford, California, USA.
出版信息
Pharmacogenet Genomics. 2012 Apr;22(4):310-8. doi: 10.1097/FPC.0b013e32834f94cb.
Abstract
摘要
相似文献
1
Celecoxib pathways: pharmacokinetics and pharmacodynamics.塞来昔布作用途径：药代动力学与药效学
Pharmacogenet Genomics. 2012 Apr;22(4):310-8. doi: 10.1097/FPC.0b013e32834f94cb.
2
Cyclooxygenase inhibitors and cardiovascular risk.环氧化酶抑制剂与心血管风险
JAMA. 2007 Feb 14;297(6):586-7; author reply 587-8. doi: 10.1001/jama.297.6.586-b.
3
Clinical use and pharmacological properties of selective COX-2 inhibitors.选择性环氧化酶-2抑制剂的临床应用及药理特性
Eur J Clin Pharmacol. 2008 Mar;64(3):233-52. doi: 10.1007/s00228-007-0400-7. Epub 2007 Nov 13.
4
Is celecoxib an inducer of cytochrome P450 3A4 in subjects carrying the CYP2C9*3 allele?对于携带CYP2C9*3等位基因的受试者，塞来昔布是细胞色素P450 3A4的诱导剂吗？
Clin Pharmacol Ther. 2006 Sep;80(3):298-301; author reply 301-02. doi: 10.1016/j.clpt.2006.05.009.
5
Cytochrome P450 2C9 genotype: impact on celecoxib safety and pharmacokinetics in a pediatric patient.细胞色素P450 2C9基因型：对一名儿科患者塞来昔布安全性和药代动力学的影响
Clin Pharmacol Ther. 2005 Sep;78(3):309-10. doi: 10.1016/j.clpt.2005.06.005.
6
Are COX-2 inhibitors safe for anyone.环氧化酶-2抑制剂对任何人都安全吗？
Inflamm Bowel Dis. 2006 Sep;12(9):922-3. doi: 10.1002/ibd.3780120913.
7
Evaluation of the relationship between polymorphisms in CYP2C8 and CYP2C9 and the pharmacokinetics of celecoxib.评估 CYP2C8 和 CYP2C9 多态性与塞来昔布药代动力学之间的关系。
J Clin Pharmacol. 2013 Dec;53(12):1261-7. doi: 10.1002/jcph.169. Epub 2013 Sep 17.
8
Accumulation of celecoxib with a 7-fold higher drug exposure in individuals homozygous for CYP2C9*3.在CYP2C9*3纯合子个体中，塞来昔布的蓄积导致药物暴露量高出7倍。
Clin Pharmacol Ther. 2006 Mar;79(3):287-8. doi: 10.1016/j.clpt.2005.11.007.
9
Risks and benefits of celecoxib to prevent recurrent adenomas.塞来昔布预防复发性腺瘤的风险与获益
N Engl J Med. 2006 Aug 31;355(9):950-2. doi: 10.1056/NEJMe068158.
10
Selective use of selective nonsteroidal anti-inflammatory drugs in inflammatory bowel disease.炎症性肠病中选择性非甾体抗炎药的选择性使用
Clin Gastroenterol Hepatol. 2006 Feb;4(2):157-9. doi: 10.1016/j.cgh.2005.11.007.
引用本文的文献
1
Cooling-Triggered Release of Celecoxib from Implantable Alginate-Soluplus Composite Devices.可植入藻酸盐-固体分散体复合装置中塞来昔布的冷却触发释放
ACS Biomater Sci Eng. 2025 Sep 8;11(9):5413-5425. doi: 10.1021/acsbiomaterials.5c00867. Epub 2025 Aug 25.
2
Evaluation of drug-drug interaction potentials between JP-1366 and celecoxib using physiologically based pharmacokinetic modeling.使用基于生理的药代动力学模型评估 JP-1366 与塞来昔布之间的药物相互作用潜力。
Transl Clin Pharmacol. 2025 Jun;33(2):90-99. doi: 10.12793/tcp.2025.33.e10. Epub 2025 Jun 27.
3
Oleuropein modulates anti-inflammatory activity of celecoxib and ketoprofen through cyclooxygenase pathway: in vivo, in silico and pharmacokinetics approaches.橄榄苦苷通过环氧化酶途径调节塞来昔布和酮洛芬的抗炎活性：体内、计算机模拟和药代动力学方法。
Naunyn Schmiedebergs Arch Pharmacol. 2025 May 30. doi: 10.1007/s00210-025-04309-2.
4
The Effects of Non-Steroidal Anti-Inflammatory Drugs Used for Orthodontic Pain Management on Tooth Movement: A Comprehensive Review of the Literature.用于正畸疼痛管理的非甾体类抗炎药对牙齿移动的影响：文献综述
J Clin Med. 2025 Apr 23;14(9):2920. doi: 10.3390/jcm14092920.
5
Enhanced delivery of anti-inflammatory therapeutics using pH-responsive histidine-modified poly-L-lysine on mesoporous silica nanoparticles.使用pH响应性组氨酸修饰的聚-L-赖氨酸增强抗炎治疗剂在介孔二氧化硅纳米颗粒上的递送。
Narra J. 2025 Apr;5(1):e1815. doi: 10.52225/narra.v5i1.1815. Epub 2025 Jan 20.
6
Selective Mapping of Brain COX-1 with [11C]PS13: Pharmacokinetic Evidence from human PET Imaging.用[11C]PS13对脑COX-1进行选择性成像：来自人体PET成像的药代动力学证据。
IBRO Neurosci Rep. 2025 Apr 17;18:657-662. doi: 10.1016/j.ibneur.2025.04.012. eCollection 2025 Jun.
7
Trends in Celecoxib Prescribing: A Single Institution 16-Month Review.塞来昔布处方趋势：单机构16个月回顾
J Clin Med. 2025 Apr 19;14(8):2823. doi: 10.3390/jcm14082823.
8
Preclinical Pharmacokinetic Assessment of a Promising Vasorelaxant, Analgesic, and Anti-Inflammatory Prototype 5-[1-(4-Fluorophenyl)-1H-pyrazol-4-yl]-2H-tetrazole (LQFM020) Through Selective Bioanalytical HPLC-PDA-Based Method.通过基于选择性生物分析HPLC-PDA的方法对一种有前景的血管舒张剂、镇痛药和抗炎原型药物5-[1-(4-氟苯基)-1H-吡唑-4-基]-2H-四唑(LQFM020)进行临床前药代动力学评估。
Biomed Chromatogr. 2025 May;39(5):e70082. doi: 10.1002/bmc.70082.
9
Self-healing injectable multifunctional hydrogels for intervertebral disc disease.用于椎间盘疾病的自愈合可注射多功能水凝胶
Mater Today Bio. 2025 Mar 11;32:101655. doi: 10.1016/j.mtbio.2025.101655. eCollection 2025 Jun.
10
BDNF/BDNF-AS Gene Polymorphisms Modulate Treatment Response and Remission in Bipolar Disorder: A Randomized Clinical Trial.BDNF/BDNF-AS基因多态性调节双相情感障碍的治疗反应和缓解：一项随机临床试验。
J Pers Med. 2025 Feb 7;15(2):62. doi: 10.3390/jpm15020062.
本文引用的文献
1
Prostaglandins and inflammation.前列腺素与炎症。
Arterioscler Thromb Vasc Biol. 2011 May;31(5):986-1000. doi: 10.1161/ATVBAHA.110.207449.
2
Five-year analysis of the prevention of colorectal sporadic adenomatous polyps trial.结直肠散发性腺瘤性息肉预防试验的 5 年分析。
Am J Gastroenterol. 2011 Jun;106(6):1135-46. doi: 10.1038/ajg.2011.116. Epub 2011 Apr 19.
3
Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis.非甾体抗炎药的心血管安全性：网络荟萃分析。
BMJ. 2011 Jan 11;342:c7086. doi: 10.1136/bmj.c7086.
4
PharmGKB summary: very important pharmacogene information for PTGS2.PharmGKB总结：关于PTGS2的非常重要的药物基因信息。
Pharmacogenet Genomics. 2011 Sep;21(9):607-13. doi: 10.1097/FPC.0b013e3283415515.
5
6
Emotion recollected in tranquility: lessons learned from the COX-2 saga.宁静中回忆的情感：COX-2 传奇中的教训。
Annu Rev Med. 2010;61:17-33. doi: 10.1146/annurev-med-011209-153129.
7
Differential effects of selective cyclooxygenase-2 inhibitors on vascular smooth muscle ion channels may account for differences in cardiovascular risk profiles.选择性环氧化酶-2抑制剂对血管平滑肌离子通道的不同作用可能解释了心血管风险状况的差异。
Mol Pharmacol. 2009 Nov;76(5):1053-61. doi: 10.1124/mol.109.057844. Epub 2009 Jul 15.
8
Variability in the response to cyclooxygenase inhibitors: toward the individualization of nonsteroidal anti-inflammatory drug therapy.环氧化酶抑制剂反应的变异性：迈向非甾体抗炎药治疗的个体化
J Investig Med. 2009 Aug;57(6):709-16. doi: 10.2310/JIM.0b013e3181b04d1f.
9
15-Hydroxyprostaglandin dehydrogenase inactivation as a mechanism of resistance to celecoxib chemoprevention of colon tumors.15-羟基前列腺素脱氢酶失活作为对塞来昔布化学预防结肠肿瘤耐药的一种机制。
Proc Natl Acad Sci U S A. 2009 Jun 9;106(23):9409-13. doi: 10.1073/pnas.0902367106. Epub 2009 May 22.
10
Nonsteroidal anti-inflammatory drugs and lower gastrointestinal complications.非甾体抗炎药与下消化道并发症
Gastroenterol Clin North Am. 2009 Jun;38(2):333-52. doi: 10.1016/j.gtc.2009.03.007.
Zotero 插件